Replimune Group Inc is a pioneering biotechnology firm based in Woburn, Massachusetts, dedicated to developing innovative cancer treatments. Founded in 2015, the company focuses on oncolytic immunotherapies, a cutting-edge approach that uses viruses to stimulate the immune system against cancer. Its flagship product, RP1, is a modified herpes virus in advanced clinical trials for various solid tumors, including a completed study for cutaneous squamous cell carcinoma. Replimune is also working on RP2 and RP3, early-stage therapies designed to enhance immune responses to cancer.
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
